MT-2A在乳腺癌组织中表达及其临床意义

Study on the expression of MT-2A in breast cancer and its clinical significance

目的探究MT-2A在乳腺癌组织中的表达及其临床意义,明确MT-2A能否作为乳腺癌的分子分型诊断标准、评估预后的分子指标。方法通过免疫组织化学染色分析各分子分型乳腺癌组织中的表达情况;通过随访对比患者生存曲线,以分析MT-2A能否作为评估乳腺癌预后的指标。结果 MT-2A在总乳腺癌标本中的阳性表达率为81%,阴性表达率为19%,MT-2A的阳性表达组中Lumina A型所占比例最高,阴性表达组中Lumina B型所占比例最高(P<0.05);MT-2A(-)表达组中无瘤生存时间为10.245年,MT-2A(+～++)无瘤生存时间为9.996年,MT-2A(+++)无瘤生存时间为10.682年,MT-2A过表达时累积无瘤生存时间最长(P<0.05)。结论 MT-2A在乳腺癌组织细胞胞浆中呈高表达,与乳腺癌的发生发展具有密切联系,且其阳性表达提示预后较好,可作为乳腺癌预后评估的参考指标。

Objective To investigate the expression of MT-2A in breast cancer and its clinical significance,and to determine whether MT-2A can be used as a molecular typing diagnostic criterion and prognostic marker of breast cancer.Methods Immunohistochemical staining was used to analyze the expression of MT-2A in breast cancer tissues with molecular typing.Survival curves of patients were compared through follow-up to analyze whether MT-2A could be used as a prognostic indicator for breast cancer.Results The positive expression rate of MT-2A was 81%and the negative expression rate was 19%.Lumina A was the highest in the positive expression group,Lumina B was the highest in the negative expression group(P<0.05),and the tumor-free survival time was 10.245 years in the MT-2A(-)expression group and 10.245 years in the MT-2A(+-++)expression group,the tumor-free survival time of MT-2A(+++)was 10.682 years,and the cumulative tumor-free survival time of MT-2A overexpression was the longest(P<0.05).Conclusion MT-2A is highly expressed in the cytoplasm of breast cancer tissues,which is closely related to the occurrence and development of breast cancer,and its positive expression indicates a better prognosis,which can be used as a reference index for prognosis evaluation of breast cancer.